36 / 40
SECUENCIA: Análisis exploratorio de tres
estudios de Panitumumab en primera línea
Peeters M et al. ESMO Open 2018;3:e000297 DOI: 10.1136/esmoopen-2017-000297
2
nd
-line
FOLFIRI
2
nd
-line
Panitumumab
+FOLFIRI
(N=29)
1
st
-line
panitumumab
+FOLFOX4
PRIME
R
PEAK
R
181
1
st
-line
+FOLFOX4
1
st
-line
panitumumab
+mFOLFOX6
1
st
-line
bevacizumab
+mFOLFOX6
2
nd
-line
VEGFI
±
Chemotherapy
(N=35)
2
nd
-line
VEGFI
±
Chemotherapy
(N=31)
vs.
vs.
OS
OS
Pooled
2
nd
-line
EGFRI
±
Chemotherapy
(N=9)
OS
1
st
-line
VEGFI
±
oxaliplatin
R
OS
Pooled
vs.